Biological markers and their use in heart failure. Consensus of Ukrainian Association of Cardiology, Ukrainian Heart Failure Association and Ukrainian Association on Acute Cardiovascular Care Working group: L.G. Voronkov, O.E. Berezin (moderators), V.Yu. Zharinova, V.M. Zhebel, O.A. Koval, Yu.S. Rudyk, O.M. Parkhomenko, V.Y. Tseluiko
Article Sidebar
Main Article Content
Abstract
Наведений консенсус присвячений обговоренню місця і ролі різних підходів до діагностики, стратифікації ризику та індивідуалізованої терапії пацієнтів із серцевою недостатністю (СН), які засновані на визначенні концентрацій біологічних маркерів, що відображають різні патофізіологічні стадії розвитку СН. Практичні рекомендації з використання біологічних маркерів при СН, що є актуальними, були введені з урахуванням категорій доказовості (табл. 1) та сили рекомендацій (табл. 2) після погодженого рішення експертів нашої країни (категорія доказів С), прийнятого на підставі ретельного аналізу даних досліджень у цій галузі. З цією метою опрацьовано дані, опубліковані за останні 5 років у вітчизняній та зарубіжній літературі, а також рекомендації зарубіжних консенсусів з діагностики, прогнозування та лікування гострої і хронічної серцевої недостатності Європейського товариства кардіологів (European Cardiology Society, 2016), Американської колегії кардіологів / Американської серцевої асоціації та Американської асоціації із серцевої недостатності (American College of Cardiology / American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America, 2017).
Консенсус адресований, насамперед, сімейним лікарям, лікарям-терапевтам і кардіологам поліклініки та стаціонарів, анестезіологам, лікарям відділень інтенсивної терапії, клінічним фармакологам, викладачам медичних вищих навчальних закладів, а також лікарям інших спеціальностей. Він може бути основою при розробленні стандартів надання медичної допомоги населенню України. У консенсусі головну увагу приділено практично орієнтованому вибору біологічних маркерів, які мають потужні властивості при встановленні первинного діагнозу СН, прогностичний потенціал при стратифікації хворих із високим ризиком маніфестації СН і прогнозуванні перебігу СН на амбулаторному та госпітальному етапах лікування.
Article Details
Keywords:
References
Ponikowski P, Voors AA, Anker SD, Bueno H, Cleland JGF, Coats AJS, Falk V, González-Juanatey JR, Harjola VP, Jankowska EA, Jessup M, Linde C, Nihoyannopoulos P, Parissis JT, Pieske B, Riley JP, Rosano GMC, Ruilope LM, Ruschitzka F, Rutten FH, van der Meer P; ESC Scientific Document Group. Authors/Task Force Members. 2016 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure: the Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur Heart J. 2016;37:2129–2200.
Wettersten N, Maisel AS. Biomarkers for Heart Failure: An Update for Practitioners of Internal Medicine. Am J Med. 2016;129(6):560–7.
Ledwidge M, Gallagher J, Conlon C, Tallon E, O'Connell E, Dawkins I, Watson C, O'Hanlon R, Bermingham M, Patle A, Badabhagni MR, Murtagh G, Voon V, Tilson L, Barry M, McDonald L, Maurer B, McDonald K. Natriuretic peptide-based screening and collaborative care for heart failure: the STOP-HF randomized trial. JAMA. 2013;310:66–74 doi: 10.1001/jama.2013.7588.
Chow SL, Maisel AS, Anand I, Bozkurt B, de Boer RA, Felker GM, Fonarow GC, Greenberg B, Januzzi JL Jr, Kiernan MS, Liu PP, Wang TJ, Yancy CW, Zile MR; American Heart Association Clinical Pharmacology Committee of the Council on Clinical Cardiology; Council on Basic Cardiovascular Sciences; Council on Cardiovascular Disease in the Young; Council on Cardiovascular and Stroke Nursing; Council on Cardiopulmonary, Critical Care, Perioperative and Resuscitation; Council on Epidemiology and Prevention; Council on Functional Genomics and Translational Biology; and Council on Quality of Care and Outcomes Research. Circulation. 2017 May 30;135(22):e1054-e1091. doi: 10.1161/CIR.0000000000000490. Epub 2017 Apr 26.
Yancy CW, Jessup M, Bozkurt B, Butler J, Casey DE Jr, Colvin MM, Drazner MH, Filippatos GS, Fonarow GC, Givertz MM, Hollenberg SM, Lindenfeld J, Masoudi FA, McBride PE, Peterson PN, Stevenson LW, Westlake C. 2017 ACC/AHA/HFSA Focused Update of the 2013 ACCF/AHA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America. Circulation. 2017;136(6):e137–61. doi: 10.1016/j.jacc.2017.04.025. Epub 2017 Apr 28.
Boulogne M, Sadoune M, Launay JM, Baudet M, Cohen-Solal A, Logeart D. Inflammation versus mechanical stretch biomarkers over time in acutely decompensated heart failure with reduced ejection fraction. Int J Cardiol. 2017;226:53–59 doi: 10.1016/j.ijcard.2016.10.038. Epub 2016 Oct 17.
Souza BSF, Silva DN, Carvalho RH, Sampaio GLA, Paredes BD, Aragão França L, Azevedo CM, Vasconcelos JF, Meira CS, Neto PC, Macambira SG, da Silva KN, Allahdadi KJ, Tavora F, de Souza Neto JD, Dos Santos RR, Soares MBP. Association of Cardiac Galectin-3 Expression, Myocarditis, and Fibrosis in Chronic Chagas Disease Cardiomyopathy. Am J Pathol. 2017;187(5):1134–1146 doi: 10.1016/j.ajpath.2017.01.016. Epub 2017 Mar 17.
Berezin AE. Up-to-date clinical approaches of biomarkers’ use in heart failure. Biomed Res Ther. 2017,4(6):1341–1370.
Hunt PJ, Yandle TG, Nicholls MG, Richards AM, Espiner EA. The aminoterminal portion of Pro-Brain natriuretic peptide (Pro-BNP) circulates in human plasma. Biochem Biophys Res Commun 1995;214:1175–83.
Hunt PJ, Richards AM, Nicholls MG, Yandle TG, Doughty RN, Espiner EA. Immunoreactive amino-terminal pro-brain natriuretic peptide (NT-PROBNP): a new marker of cardiac impairment. Clin Endocrinol 1997;47:287–96.
Espiner EA, Richards AM. Atrial natriuretic peptide. An important factor in sodium and blood pressure regulation. Lancet 1989;333:707–10.
Maisel AS, McCord J, Nowak RM, et al. Bedside B-type natriuretic peptide in the emergency diagnosis of heart failure with reduced or preserved ejection fraction results from the breathing not properly multinational study. J Am Coll Cardiol 2003;41:2010–7.
O'Donoghue M, Chen A, Baggish AL, Anwaruddin S, Krauser DG, Tung R, Januzzi JL.The effects of ejection fraction on N-terminal ProBNP and BNP levels in patients with acute CHF: analysis from the ProBNP investigation of dyspnea in the emergency department (PRIDE) study. J Card Fail 2005;11(Suppl 5):S9–14.
Troughton RW, Richards AM. B-type natriuretic peptides and echocardiographic measures of cardiac structure and function. JACC Cardiovasc Imaging 2009;2:216–25.
Iwanaga Y, Nishi I, Furuichi S, Noguchi T, Sase K, Kihara Y, Goto Y, Nonogi H. B-type natriuretic peptide strongly reflects diastolic wall stress in patients with chronic heart failure comparison between systolic and diastolic heart failure. J Am Coll Cardiol 2006;47:742–8.
Kraigher-Krainer E, Shah AM, Gupta DK, Santos A, Claggett B, Pieske B, Zile MR, Voors AA, Lefkowitz MP, Packer M, McMurray JJ, Solomon SD; PARAMOUNT Investigators. Impaired systolic function by strain imaging in heart failure with preserved ejection fraction. J Am Coll Cardiol 2014;63:447–56. doi: 10.1016/j.jacc.2013.09.052. Epub 2013 Oct 30.
Januzzi JL, van Kimmenade R, Lainchbury J, Bayes-Genis A, Ordonez-Llanos J, Santalo-Bel M, Pinto YM, Richards M. NT-proBNP testing for diagnosis and short-term prognosis in acute destabilized heart failure: an international pooled analysis of 1256 patients: the International Collaborative of NT-proBNP Study. Eur Heart J 2006;27:330–7.
Bayes-Genis A, Barallat J, Richards AM. A test in context. Neprilysin: function, inhibition and biomarker. J Am Coll Cardiol 2016;68:639–53.
Packer M, McMurray JJ, Desai AS, Gong J, Lefkowitz MP, Rizkala AR, Rouleau JL, Shi VC, Solomon SD, Swedberg K, Zile M, Andersen K, Arango JL, Arnold JM, Bělohlávek J, Böhm M, Boytsov S, Burgess LJ, Cabrera W, Calvo C, Chen CH, Dukat A, Duarte YC, Erglis A, Fu M, Gomez E, Gonzàlez-Medina A, Hagège AA, Huang J, Katova T, Kiatchoosakun S, Kim KS, Kozan Ö, Llamas EB, Martinez F, Merkely B, Mendoza I, Mosterd A, Negrusz-Kawecka M, Peuhkurinen K, Ramires FJ, Refsgaard J, Rosenthal A, Senni M, Sibulo AS Jr, Silva-Cardoso J, Squire IB, Starling RC, Teerlink JR, Vanhaecke J, Vinereanu D, Wong RC; PARADIGM-HF Investigators and Coordinators. PARADIGM-HF Investigators and Coordinators. Angiotensin receptor neprilysin inhibition compared with enalapril on the risk of clinical progression in surviving patients with heart failure. Circulation 2015;131:54–61. doi: 10.1161/CIRCULATIONAHA.114.013748. Epub 2014 Nov 17.
Costello-Boerrigter LC, Boerrigter G, Redfield MM, Rodeheffer RJ, Urban LH, Mahoney DW, Jacobsen SJ, Heublein DM, Burnett JC Jr. Amino-terminal pro-B-type natriuretic peptide and B-type natriuretic peptide in the general community: determinants and detection of left ventricular dysfunction. J Am Coll Cardiol 2006;47:345–53.
Zaphiriou A, Robb S, Murray-Thomas T, Mendez G, Fox K, McDonagh T, Hardman SM, Dargie HJ, Cowie MR. The diagnostic accuracy of plasma BNP and NTproBNP in patients referred from primary care with suspected heart failure: results of the UK natriuretic peptide study. Eur. J.Heart Fail. 2005;7:537–41.
Son CS, Kim YN, Kim HS, Park HS, Kim MS. Decision-making model for early diagnosis of congestive heart failure using rough set and decision tree approaches. J Biomed Inform. 2012;45:999–1008. doi: 10.1016/j.jbi.2012.04.013. Epub 2012 May 4.
Kelder JC, Cramer MJ, van Wijngaarden J, van Tooren R, Mosterd A, Moons KG, Lammers JW, Cowie MR, Grobbee DE, Hoes AW. The diagnostic value of physical examination and additional testing in primary care patients with suspected heart failure. Circulation. 2011;124:2865–73.
Richards AM, Doughty R, Nicholls MG, MacMahon S, Sharpe N, Murphy J, Espiner EA, Frampton C, Yandle TG; Australia-New Zealand Heart Failure Group. Plasma N-terminal pro-brain natriuretic peptide and adrenomedullin: prognostic utility and prediction of benefit from carvedilol in chronic ischemic left ventricular dysfunction. Australia-New Zealand Heart Failure Group. J Am Coll Cardiol. 2001;37:1781–7.
Tang WH, Girod JP, Lee MJ, Starling RC, Young JB, Van Lente F, Francis GS. Plasma B-type natriuretic peptide levels in ambulatory patients with established chronic symptomatic systolic heart failure. Circulation. 2003; 108:2964–6.
Booth RA, Hill SA, Don-Wauchope A, Santaguida PL, Oremus M, McKelvie R, Balion C, Brown JA, Ali U, Bustamam A, Sohel N, Raina P. Performance of BNP and NT-proBNP for diagnosis of heart failure in primary care patients: a systematic review. Heart Fail Rev. 2014;19:439–51. doi: 10.1007/s10741-014-9445-8.
Anwaruddin S, Lloyd-Jones DM, Baggish A, Chen A, Krauser D, Tung R, Chae C, Januzzi JL Jr. Renal function, congestive heart failure, and aminoterminal pro-brain natriuretic peptide measurement: results from the ProBNP Investigation of Dyspnea in the Emergency Department (PRIDE) Study. J Am Coll Cardiol. 2006;47:91–7.
Redfield MM, Rodeheffer RJ, Jacobsen SJ, Mahoney DW, Bailey KR, Burnett JC Jr. Plasma brain natriuretic peptide concentration: impact of age and gender. J Am Coll Cardiol. 2002;40:976–82.
Wang TJ, Larson MG, Levy D, Leip EP, Benjamin EJ, Wilson PW, Sutherland P, Omland T, Vasan RS. Impact of age and sex on plasma natriuretic peptide levels in healthy adults. Am J Cardiol. 2002; 90:254-8.
Chang AY, Abdullah SM, Jain T, Stanek HG, Das SR, McGuire DK, Auchus RJ, de Lemos JA. Associations among androgens, estrogens, and natriuretic peptides in young women: observations from the Dallas Heart Study. J Am Coll Cardiol. 2007;49:109–16.
Masson S, Latini R, Anand IS, Vago T, Angelici L, Barlera S, Missov ED, Clerico A, Tognoni G, Cohn JN; Val-HeFT Investigators. Direct comparison of B-type natriuretic peptide (BNP) and aminoterminal proBNP in a large population of patients with chronic and symptomatic heart failure: the Valsartan Heart Failure (Val-HeFT) Data. Clin Chem 2006;52:1528–38.
Anand IS, Rector TS, Cleland JG, Kuskowski M, McKelvie RS, Persson H, McMurray JJ, Zile MR, Komajda M, Massie BM, Carson PE. Prognostic value of baseline plasma amino-terminal pro-brain Natriuretic peptide and its interactions with Irbesartan treatment effects in patients with heart failure and preserved ejection fraction: findings from the I-PRESERVE Trial. Circ Heart Fail 2011;4:569–77. doi: 10.1161/CIRCHEARTFAILURE.111.962654. Epub 2011 Jun 29.
Zile MR, Claggett BL, Prescott MF, McMurray JJ, Packer M, Rouleau JL, Swedberg K, Desai AS, Gong J, Shi VC, Solomon SD. Prognostic implications of changes in N-Terminal Pro-B-Type Natriuretic peptide in patients with heart failure. J Am Coll Cardiol 2016;68:2425–36. doi: 10.1016/j.jacc.2016.09.931.
The Guiding Evidence Based Therapy Using Biomarker Intensified Treatment (GUIDE-IT) trial (ClinicalTrials.gov NCT01685840).
Allen LA, Matlock DD, Shetterly SM, Xu S, Levy WC, Portalupi LB, McIlvennan CK, Gurwitz JH, Johnson ES, Smith DH, Magid DJ. Use of risk models to predict death in the next year among individual ambulatory patients with heart failure. JAMA Cardiol 2017;2(4):435–41. doi: 10.1001/jamacardio.2016.5036.
Savarese G, Trimarco B, Dellegrottaglie S, Prastaro M, Gambardella F, Rengo G, Leosco D, Perrone-Filardi P. Natriuretic peptide-guided therapy in chronic heart failure: a meta-analysis of 2,686 patients in 12 randomized trials. PLoS One 2013;8:58287. doi: 10.1371/journal.pone.0058287. Epub 2013 Mar 5.
Troughton RW, Frampton CM, Brunner-La Rocca HP, Pfisterer M, Eurlings LW, Erntell H, Persson H, O'Connor CM, Moertl D, Karlström P, Dahlström U, Gaggin HK, Januzzi JL, Berger R, Richards AM, Pinto YM, Nicholls MG. Effect of B-type natriuretic peptide-guided treatment of chronic heart failure on total mortality and hospitalization: an individual patient meta-analysis. Eur Heart J 2014;35:1559–67. doi: 10.1093/eurheartj/ehu090. Epub 2014 Mar 6.
Ledwidge M, Gallagher J, Conlon C, Tallon E, O'Connell E, Dawkins I, Watson C, O'Hanlon R, Bermingham M, Patle A, Badabhagni MR, Murtagh G, Voon V, Tilson L, Barry M, McDonald L, Maurer B, McDonald K. Natriuretic peptide-based screening and collaborative care for heart failure: the STOP-HF randomized trial. JAMA. 2013;310:66–74. doi: 10.1001/jama.2013.7588.
Huelsmann M, Neuhold S, Resl M, Strunk G, Brath H, Francesconi C, Adlbrecht C, Prager R, Luger A, Pacher R, Clodi M. PONTIAC (NT-proBNP selected prevention of cardiac events in a population of diabetic patients without a history of cardiac disease): a prospective randomized controlled trial. J.Am. Coll. Cardiol. 2013; 62:1365-72. doi: 10.1016/j.jacc.2013.05.069. Epub 2013 Jun 27.
Lala RI, Lungeanu D, Darabantiu D, Pilat L, Puschita M. Galectin-3 as a marker for clinical prognosis and cardiac remodeling in acute heart failure. Herz. 2017. Doi: 10.1007/s00059-017-4538-5. [Epub ahead of print]
Imran TF, Shin HJ, Mathenge N, Wang F, Kim B, Joseph J, Gaziano JM, Djoussé L. Meta-Analysis of the Usefulness of Plasma Galectin-3 to Predict the Risk of Mortality in Patients With Heart Failure and in the General Population. Am J Cardiol. 2017;119(1):57–64. doi: 10.1016/j.amjcard.2016.09.019. Epub 2016 Sep 29.
Besler C, Lang D, Urban D, Rommel KP, von Roeder M, Fengler K, Blazek S, Kandolf R, Klingel K, Thiele H, Linke A, Schuler G, Adams V, Lurz P. Plasma and Cardiac Galectin-3 in Patients With Heart Failure Reflects Both Inflammation and Fibrosis: Implications for Its Use as a Biomarker. Circ Heart Fail. 2017;10(3). Doi: 10.1161/CIRCHEARTFAILURE.116.003804
Srivatsan V, George M, Shanmugam E. Utility of galectin-3 as a prognostic biomarker in heart failure: where do we stand? Eur J Prev Cardiol. 2015;22(9):1096–110.
Boulogne M, Sadoune M, Launay JM, Baudet M, Cohen-Solal A, Logeart D. Inflammation versus mechanical stretch biomarkers over time in acutely decompensated heart failure with reduced ejection fraction. Int J Cardiol. 2017;226:53–59. doi: 10.1016/j.ijcard.2016.10.038. Epub 2016 Oct 17.
Billebeau G, Vodovar N, Sadoune M, Launay JM, Beauvais F, Cohen-Solal A. Effects of a cardiac rehabilitation programme on plasma cardiac biomarkers in patients with chronic heart failure. Eur J Prev Cardiol. 2017. Doi: 10.1177/2047487317705488. [Epub ahead of print]
Berezin AE. Circulating Biomarkers in Heart Failure. Advances in Internal Medicine. 2018;1067:89–108.
Karayannis G, Triposkiadis F, Skoularigis J, Georgoulias P, Butler J, Giamouzis G.The emerging role of Galectin-3 and ST2 in heart failure: practical considerations and pitfalls using novel biomarkers. Curr. Heart Fail. Rep. 2013;10:441–9. doi: 10.1007/s11897-013-0169-1.
Ahmad T, Fiuzat M, Neely B, Neely ML, Pencina MJ, Kraus WE, Zannad F, Whellan DJ, Donahue MP, Piña IL, Adams KF, Kitzman DW, O'Connor CM, Felker GM. Biomarkers of myocardial stress and fibrosis as predictors of mode of death in patients with chronic heart failure. JACC Heart Fail. 2014;2:260–8. doi: 10.1016/j.jchf.2013.12.004.
Bayes-Genis A, de Antonio M, Vila J, Peñafiel J, Galán A, Barallat J, Zamora E, Urrutia A, Lupón J. Head-to-head comparison of 2 myocardial fibrosis biomarkers for long-term heart failure risk stratification: ST2 versus galectin-3. J. Am. Coll. Cardiol. 2014;63:158–66. doi: 10.1016/j.jacc.2013.07.087. Epub 2013 Sep 24.
Gaggin HK, Szymonifka J, Bhardwaj A, Belcher A, De Berardinis B, Motiwala S, Wang TJ, Januzzi JL Jr. Head-to-head comparison of serial soluble ST2, growth differentiation factor-15, and highly-sensitive troponin T measurements in patients with chronic heart failure. JACC Heart Fail. 2014;2:65–72. doi: 10.1016/j.jchf.2013.10.005. Epub 2014 Jan 25.
Ahmad T, Fiuzat M, Pencina MJ, Geller NL, Zannad F, Cleland JG, Snider JV, Blankenberg S, Adams KF, Redberg RF, Kim JB, Mascette A, Mentz RJ, O'Connor CM, Felker GM, Januzzi JL. Charting a roadmap for heart failure biomarker studies. JACC Heart Fail. 2014;2:477–88. doi: 10.1016/j.jchf.2014.02.005. Epub 2014 Jun 11.
Shah RV, Chen-Tournoux AA, Picard MH, van Kimmenade RR, Januzzi JL. Galectin-3, cardiac structure and function, and long-term mortality in patients with acutely decompensated heart failure. Eur. J. Heart Fail. 2010; 12:826–32. doi: 10.1093/eurjhf/hfq091. Epub 2010 Jun 5.
de Boer RA, Lok DJ, Jaarsma T, van der Meer P, Voors AA, Hillege HL, van Veldhuisen DJ. Predictive value of plasma galectin-3 levels in heart failure with reduced and preserved ejection fraction. Ann. Med. 2011;43:60–8. doi: 10.3109/07853890.2010.538080. Epub 2010 Dec 28.
Lok DJ, Van Der Meer P, de la Porte PW, Lipsic E, Van Wijngaarden J, Hillege HL, van Veldhuisen DJ.Prognostic value of galectin-3, a novel marker of fibrosis, in patients with chronic heart failure: data from the DEAL-HF study. Clin. Res. Cardiol. 2010;99:323–8. doi: 10.1007/s00392-010-0125-y. Epub 2010 Feb 4.
Tang WH, Shrestha K, Shao Z, Borowski AG, Troughton RW, Thomas JD, Klein AL.Usefulness of plasma galectin-3 levels in systolic heart failure to predict renal insufficiency and survival. Am J Cardiol. 2011;108:385–90. doi: 10.1016/j.amjcard.2011.03.056. Epub 2011 May 19.
Krintus M, Kozinski M, Fabiszak T, Kubica J, Panteghini M, Sypniewska G. Establishing reference intervals for galectin-3 concentrations in serum requires careful consideration of its biological determinants. Clin Biochem. 2017 doi: 10.1016/j.clinbiochem.2017.03.015. [Epub ahead of print]
Rehman SU, Mueller T, Januzzi JL Jr. Characteristics of the novel interleukin family biomarker ST2 in patients with acute heart failure. J. Am. Coll. Cardiol. 2008;52:1458–65.
Meijers WC, van der Velde AR, Muller Kobold AC, Dijck-Brouwer J, Wu AH, Jaffe A, de Boer RA. Variability of biomarkers in patients with chronic heart failure and healthy controls. Eur J Heart Fail. 2017;19(3):357–365. doi: 10.1002/ejhf.669. Epub 2016 Oct 21.
Miró Ò, González de la Presa B, Herrero-Puente P, Fernández Bonifacio R, Möckel M, Mueller C, Casals G, Sandalinas S, Llorens P, Martín-Sánchez FJ, Jacob J, Bedini JL, Gil V. The GALA study: relationship between galectin-3 serum levels and short- and long-term outcomes of patients with acute heart failure. Biomarkers. 2017;2:1–9. doi: 10.1080/1354750X.2017.1319421. Epub 2017 May 2.
Wojciechowska C, Romuk E, Nowalany-Kozielska E, Jacheć W. Serum Galectin-3 and ST2 as predictors of unfavorable outcome in stable dilated cardiomyopathy patients. Hellenic J Cardiol. 2017. Doi: 10.1016/j.hjc.2017.03.006. [Epub ahead of print]
Maisel AS, Di Somma S. Do we need another heart failure biomarker: focus on soluble suppression of tumorigenicity 2 (sST2). Eur Heart J. 2016. Doi: 10.1093/eurheartj/ehw462. [Epub ahead of print]
Januzzi JL Jr, Peacock WF, Maisel AS, Chae CU, Jesse RL, Baggish AL, O'Donoghue M, Sakhuja R, Chen AA, van Kimmenade RR, Lewandrowski KB, Lloyd-Jones DM, Wu AH. Measurement of the interleukin family member ST2 in patients with acute dyspnea: results from the PRIDE (Pro-Brain Natriuretic Peptide Investigation of Dyspnea in the Emergency Department) study. J. Am. Coll. Cardiol. 2007;50:607–13
Tang WH, Wu Y, Grodin JL, Hsu AP, Hernandez AF, Butler J, Metra M, Voors AA, Felker GM, Troughton RW, Mills RM, McMurray JJ, Armstrong PW, O'Connor CM, Starling RC. Prognostic Value of Baseline and Changes in Circulating Soluble ST2 Levels and the Effects of Nesiritide in Acute Decompensated Heart Failure. JACC Heart Fail. 2016; 4:68–77. doi: 10.1016/j.jchf.2015.07.015. Epub 2015 Dec 2.
Januzzi JL, Mebazaa A, Di SS. ST2 and prognosis in acutely decompensated heart failure: the International ST2 Consensus Panel. Am J Cardiol. 2015; 115:26B–31B.
Mebazaa A, Di Somma S, Maisel AS, Bayes-Genis A. ST2 and multimarker testing in acute decompensated heart failure. Am J Cardiol. 2015;115:38B–43B. doi: 10.1016/j.amjcard.2015.01.039. Epub 2015 Jan 23.
Wong PC, Guo J, Zhang A. The renal and cardiovascular effects of natriuretic peptides. Absence of clear clinical recommendations of biomarker-based HF therapy is the main cause of uncertainty regarding practical use of this approach. Adv Physiol Educ. 2017;41(2):179–185
Tseluyko VI, Lozovaya TA. Levels of galectin-3. cerebral natriuretic peptide and the state of diastolic function of the left and right ventricles in patients with myocardial infarction with Q wave of the posterior wall of the left ventricle with the involvement of the right ventricle. Sertse i sudyny [Heart and blood vessels]. 2013;3:65–71.
Tseluyko VI, Matviychuk NV, Kinoshenko KYu. Dynamics of changes in the level of galectin-3 in patients with chronic heart failure with a six-month observation. International medical journal. 2013;2:35–39.
de Lemos JA. Increasingly sensitive assays for cardiac troponins: a review. JAMA. 2013;309:2262–9.
Anguita M. High-sensitivity troponins and prognosis of heart failure. Rev Clin Esp. 2017;217(2):95–96.
Nagarajan V, Hernandez AV, Tang WH. Prognostic value of cardiac troponin in chronic stable heart failure: a systematic review. Heart. 2012;98(24):1778–86
Dierkes J, Domröse U, Westphal S, Ambrosch A, Bosselmann HP, Neumann KH, Luley C. Cardiac troponin T predicts mortality in patients with end-stage renal disease. Circulation. 2000;102:1964–1969.
Recommendations of the Association of Cardiologists of Ukraine for the Diagnosis and Treatment of Chronic Heart Failure / Ed. LGVoronkova. Ukr cardiol journ, 2018;3:11–76.
Petyunina OV, Kopytsya MP, Rudyk YS, Isayeva GS. Promising Role of Vascular Endothelial Growth Factor-A in Risk Stratification after PCI / In: Vascular access surgery: tip and trics. InTech, London, 2019. doi: 10.5772/intechopen.82712
Ilva T, Lassus J, Siirilä-Waris K, Melin J, Peuhkurinen K, Pulkki K, Nieminen MS, Mustonen H, Porela P, Harjola VP. Clinical significance of cardiac troponins I and T in acute heart failure. Eur. J. Heart Fail. 2008;10(8):772–779. doi: 10.1016/j.ejheart.2008.06.009. Epub 2008 Jul 2.
Mueller C. Risk stratification in acute decompensated heart failure: the role of cardiac troponin. Nat. Clin. Pract. Cardiovasc. Med. 2008;5(11):680–681.